# 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)

> **NCT00684619** · PHASE2 · COMPLETED · sponsor: **Goethe University** · enrollment: 120 (actual)

## Conditions studied

- T-ALL, T-NHL (Lymphoblastic)

## Interventions

- **DRUG:** Nelarabine

## Key facts

- **NCT ID:** NCT00684619
- **Lead sponsor:** Goethe University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684619, "506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00684619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*